Dr. Reddy's Laboratories Limited (RDY) News
Track canonical SquawkNews coverage tagged to RDY, Dr. Reddy's Laboratories Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 20 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Dr Reddy's Laboratories Q1 2027 Earnings Call Transcript
Dr Reddy's Laboratories (NYSE: RDY ) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transc
LIVE | Sep 17, 2026, 07:42 AM UTC
L
ReadyTech target price raised to A$2.25 by Morgans
Morgans raised its ReadyTech target price by 4.7% to A$2.25 per share for RDY.AU.
EQUITY | Aug 31, 2026, 11:38 PM UTC
L
ReadyTech price target raised to A$1.55 by Canaccord Genuity
Canaccord Genuity raised its ReadyTech price target by 16% to A$1.55 per share.
EQUITY | Aug 27, 2026, 11:32 PM UTC
L
RDY: AI transformation, cost discipline, and strategic wins position for margin recovery in FY 2027
RDY: AI transformation, cost discipline, and strategic wins position for margin recovery in FY 2027
EQUITY | Aug 27, 2026, 02:09 AM UTC
L
RDY: cost discipline and AI adoption support growth outlook
RDY cites cost discipline, AI adoption, and enterprise wins as positioning for margin and revenue growth ahead.
EARNINGS | Aug 27, 2026, 01:37 AM UTC
M
RDY reports FY26 modest revenue growth amid margin pressure
RDY’s FY26 delivered modest revenue growth, margin pressure, and strong AI-driven operational gains.
EQUITY | Aug 27, 2026, 12:14 AM UTC
L
RDY: Flagship growth and AI gains offset churn, with FY27 guidance targeting margin recovery
RDY: Flagship growth and AI gains offset churn, with FY27 guidance targeting margin recovery
EARNINGS | Aug 26, 2026, 10:35 PM UTC
L
RDY revenue up; losses narrowed; recurring strong, margins pressured
RDY reported revenue growth and narrowed losses, with strong recurring revenue. Margins were pressured and growth was expected.
EQUITY | Aug 26, 2026, 10:28 PM UTC
L
ReadyTech will not pay a final dividend
ReadyTech says it will not pay a final dividend.
EQUITY | Aug 26, 2026, 10:06 PM UTC
L
ReadyTech FY revenue A$125.0 million, up 2.6%
ReadyTech reported FY revenue of A$125.0 million, up 2.6%.
EQUITY | Aug 26, 2026, 10:05 PM UTC
M
ReadyTech FY net loss A$4.9 million, down 70%
ReadyTech reported FY net loss of A$4.9 million, down 70%.
EQUITY | Aug 26, 2026, 10:05 PM UTC
H
India's Dr Reddy's receives FDA Form 483
Dr Reddy's gets FDA Form 483 with three observations
REGULATION | Jul 29, 2026, 04:15 PM UTC
L
RDY Dr reddy's exec - been good traction for our Semaglutide product in market - Do not see any concerns on stock, inventory - Overall india
RDY Dr reddy's exec - been good traction for our Semaglutide product in market - Do not see any concerns on stock, inventory - Overall indian market will continue to grow double-digit
EQUITY | Jul 22, 2026, 12:40 PM UTC
L
RDY Dr reddy's exec on Semaglutide- we understood chemistry and rootcause, results are expected in September Dr reddy's exec on Semaglutide
RDY Dr reddy's exec on Semaglutide- we understood chemistry and rootcause, results are expected in September Dr reddy's exec on Semaglutide- hopefully will get Semaglutide to market by November
EQUITY | Jul 22, 2026, 12:27 PM UTC
H
RDY Dr reddy's exec on tariff - not going to do anything special immediately due to tariff announcement, will assess
RDY Dr reddy's exec on tariff - not going to do anything special immediately due to tariff announcement, will assess
GEOPOLITICS | Jul 22, 2026, 12:27 PM UTC
H
RDY Dr reddy's exec on tariff - if tariff is imposed, will raise prices in the U.S.
RDY Dr reddy's exec on tariff - if tariff is imposed, will raise prices in the U.S.
GEOPOLITICS | Jul 22, 2026, 12:27 PM UTC
H
RDY Dr reddy's exec on tariff- been in these cycles before, not practical to move to U.S. immediately
RDY Dr reddy's exec on tariff- been in these cycles before, not practical to move to U.S. immediately
GEOPOLITICS | Jul 22, 2026, 12:26 PM UTC
L
RDY Dr reddy's exec- elevated frieght costs due to middle East issues, high solvent prices impacted EBITDA this qtr Dr reddy's exec- launche
RDY Dr reddy's exec- elevated frieght costs due to middle East issues, high solvent prices impacted EBITDA this qtr Dr reddy's exec- launched generic Semaglutide tablets in India Dr reddy's exec- working to resume Semagl
EQUITY | Jul 22, 2026, 12:20 PM UTC
L
RDY Dr. Reddy's RESULTS: Q1, Q1 consol total REV from ops 81B rupees; consensus est. 81.6B rupees, Q1 consol net Pat 4.44B rupees; consensus
RDY Dr. Reddy's RESULTS: Q1, Q1 consol total REV from ops 81B rupees; consensus est. 81.6B rupees, Q1 consol net Pat 4.44B rupees; consensus est. 7.22B rupees
EQUITY | Jul 22, 2026, 11:19 AM UTC
H
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call
Dr Reddy's Laboratories (NYSE: RDY ) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and fi
EARNINGS | Jul 01, 2026, 08:20 AM UTC